N@N

Derma Sciences to Present at the Noble Financial Capital Marketsa? Seventh Annual Equity Conference

_{//health-fitness.news-articles.net/content/2011/ .. l-marketsa-seventh-annual-equity-conference.html}
^{Published in Health and Fitness on Friday, May 13th 2011 at 10:50 GMT by Market Wire}  

PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will be presenting at the Noble Financial Capital Marketsa™ Seventh Annual Equity Conference being held at the Seminole Hard Rock Hotel & Casino in Hollywood, Fla. on May 16 and 17. Barry Wolfenson, Derma Sciencesa™ Executive Vice President of Global Marketing & Business Development will deliver the Companya™s corporate presentation on Tuesday, May 17 at 12:30 p.m. Eastern time.

At the time of the presentation, a live audio and high-definition video webcast of Derma Sciencesa™ presentation and a copy of the presentation materials will be available at [ www.dermasciences.com ] or through the Noble Financial websites: [ www.noblefcm.com ], or [ www.noble7.com ]. The Company recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. Participants will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will also be archived on the Companya™s website for 90 days following the event.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention. For more information please visit [ www.dermasciences.com ].

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.